These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 20061157)

  • 1. 4-Aryl-4-oxo-N-phenyl-2-aminylbutyramides as acetyl- and butyrylcholinesterase inhibitors. Preparation, anticholinesterase activity, docking study, and 3D structure-activity relationship based on molecular interaction fields.
    Vitorović-Todorović MD; Juranić IO; Mandić LM; Drakulić BJ
    Bioorg Med Chem; 2010 Feb; 18(3):1181-93. PubMed ID: 20061157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural modifications of 4-aryl-4-oxo-2-aminylbutanamides and their acetyl- and butyrylcholinesterase inhibitory activity. Investigation of AChE-ligand interactions by docking calculations and molecular dynamics simulations.
    Vitorović-Todorović MD; Koukoulitsa C; Juranić IO; Mandić LM; Drakulić BJ
    Eur J Med Chem; 2014 Jun; 81():158-75. PubMed ID: 24836068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.
    Campiani G; Fattorusso C; Butini S; Gaeta A; Agnusdei M; Gemma S; Persico M; Catalanotti B; Savini L; Nacci V; Novellino E; Holloway HW; Greig NH; Belinskaya T; Fedorko JM; Saxena A
    J Med Chem; 2005 Mar; 48(6):1919-29. PubMed ID: 15771436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docking and quantum mechanic studies on cholinesterases and their inhibitors.
    Correa-Basurto J; Flores-Sandoval C; Marín-Cruz J; Rojo-Domínguez A; Espinoza-Fonseca LM; Trujillo-Ferrara JG
    Eur J Med Chem; 2007 Jan; 42(1):10-9. PubMed ID: 17055616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, biological activity, and docking studies of new acetylcholinesterase inhibitors of the bispyridinium type.
    Kapková P; Stiefl N; Sürig U; Engels B; Baumann K; Holzgrabe U
    Arch Pharm (Weinheim); 2003 Nov; 336(11):523-40. PubMed ID: 14639745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and evaluation of flavonoid derivatives as potent AChE inhibitors.
    Sheng R; Lin X; Zhang J; Chol KS; Huang W; Yang B; He Q; Hu Y
    Bioorg Med Chem; 2009 Sep; 17(18):6692-8. PubMed ID: 19692250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors.
    Huang L; Shi A; He F; Li X
    Bioorg Med Chem; 2010 Feb; 18(3):1244-51. PubMed ID: 20056426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors.
    Asadipour A; Alipour M; Jafari M; Khoobi M; Emami S; Nadri H; Sakhteman A; Moradi A; Sheibani V; Homayouni Moghadam F; Shafiee A; Foroumadi A
    Eur J Med Chem; 2013; 70():623-30. PubMed ID: 24211638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
    Camps P; Formosa X; Galdeano C; Gómez T; Muñoz-Torrero D; Scarpellini M; Viayna E; Badia A; Clos MV; Camins A; Pallàs M; Bartolini M; Mancini F; Andrisano V; Estelrich J; Lizondo M; Bidon-Chanal A; Luque FJ
    J Med Chem; 2008 Jun; 51(12):3588-98. PubMed ID: 18517184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues.
    Bolognesi ML; Bartolini M; Cavalli A; Andrisano V; Rosini M; Minarini A; Melchiorre C
    J Med Chem; 2004 Nov; 47(24):5945-52. PubMed ID: 15537349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of physostigmine analogues and evaluation of their anticholinesterase activities.
    Zhan ZJ; Bian HL; Wang JW; Shan WG
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1532-4. PubMed ID: 20144867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine.
    Tumiatti V; Rosini M; Bartolini M; Cavalli A; Marucci G; Andrisano V; Angeli P; Banzi R; Minarini A; Recanatini M; Melchiorre C
    J Med Chem; 2003 Mar; 46(6):954-66. PubMed ID: 12620072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation, anticholinesterase activity and molecular docking of new lupane derivatives.
    Castro MJ; Richmond V; Romero C; Maier MS; Estévez-Braun A; Ravelo AG; Faraoni MB; Murray AP
    Bioorg Med Chem; 2014 Jul; 22(13):3341-50. PubMed ID: 24835788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
    Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH
    Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors.
    Carolan CG; Dillon GP; Gaynor JM; Reidy S; Ryder SA; Khan D; Marquez JF; Gilmer JF
    J Med Chem; 2008 Oct; 51(20):6400-9. PubMed ID: 18817366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and evaluation of isaindigotone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors.
    Pan L; Tan JH; Hou JQ; Huang SL; Gu LQ; Huang ZS
    Bioorg Med Chem Lett; 2008 Jul; 18(13):3790-3. PubMed ID: 18524585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for Myasthenia gravis implications.
    Musilek K; Komloova M; Zavadova V; Holas O; Hrabinova M; Pohanka M; Dohnal V; Nachon F; Dolezal M; Kuca K; Jung YS
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1763-6. PubMed ID: 20138518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel tricyclic quinazolinimines and related tetracyclic nitrogen bridgehead compounds as cholinesterase inhibitors with selectivity towards butyrylcholinesterase.
    Decker M; Krauth F; Lehmann J
    Bioorg Med Chem; 2006 Mar; 14(6):1966-77. PubMed ID: 16289855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors.
    Savini L; Gaeta A; Fattorusso C; Catalanotti B; Campiani G; Chiasserini L; Pellerano C; Novellino E; McKissic D; Saxena A
    J Med Chem; 2003 Jan; 46(1):1-4. PubMed ID: 12502352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study on dual-site inhibitors of acetylcholinesterase: Highly potent derivatives of bis- and bifunctional huperzine B.
    He XC; Feng S; Wang ZF; Shi Y; Zheng S; Xia Y; Jiang H; Tang XC; Bai D
    Bioorg Med Chem; 2007 Feb; 15(3):1394-408. PubMed ID: 17126020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.